Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.
An article from
Dive Brief
Notably, Novartis revealed that remibrutinib wasn’t associated with the kind of liver-related side effects other BTK inhibitors like it have encountered.
Published Sept. 1, 2026
General view of the Swiss pharmaceutical and drug company Novartis AG headquarters on April 11, 2025 in Basel, Switzerland.
Novartis stock rises after MS drug remibrutinib trial results
Novartis, Remibrutinib centra gli obiettivi sulla sclerosi multipla. In secondo piano lo stop a otto studi su Rap-cel | MilanoFinanza News
Novartis sale con l"anti-sclerosi | MilanoFinanza News
Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest
Novartis, Bristol Myers halt autoimmune CAR-T trials after deaths
Novartis pushes ahead with its IL-6 inhibitor despite Novo’s failure
Novartis halts clinical trials following patient deaths
Novartis Drug Fails Key Test for New Heart Disease Approach
Will Patient Deaths Derail the CAR-T Train in Autoimmune Disease?
The oral drug remibrutinib cut relapse rates in patients with relapsing multiple sclerosis, beating a rival treatment in both…
Ubs stima una probabilità del 50% di successo per il farmaco sperimentale Remibrutinib con vendite al picco previste a 4,5…
Ubs stima il 50% di probabilità di successo per il farmaco Remibrutinib: picco di vendite previsto a 4,5 miliardi $ Mambretti…
Novartis' Rhapsido cuts MS relapse rates and shows a clean safety profile in Phase 3 trials; Jefferies sees peak sales above $3B.
Novartis paused 8 trials of its rap-cel therapy after patients died from a severe immune reaction; Bristol Myers followed as a…
Novartis plans Phase 3 trial of pacibekitug for CV risk reduction despite Novo Nordisk's failed ZEUS trial of ziltivekimab.…
